Zhittya Genesis Medicine is CardioVascular Biotherapeutics (Venturis Therapeutics) only competitor in the development of FGF-1. Zhittya Genesis Medicine was founded by the former CEO and founder of CVBT, Dan Montano. Zhittya Genesis Medicine has since soared to the top since he left CVBT in 2014.
Under the Marketplace Exclusivity, the first company to obtain approval gets an effective monopoly for 10 years. With Zhittya Genesis Medicine (ZGM) indubitably ahead of Venturis Therapeutics by about six years, it is clear who will be the first to monopolize the FGF-1 industry.
Zhittya Genesis Medicine and Venturis/CVBT are the only two companies in the race to commercialize FGF-1. Clearly Zhittya Genesis Medicine is far ahead of Venturis in the race as their announcements clearly state that they now have a large batch of FGF-1 at their disposal, have started numerous clinical trials such as in Parkinson's Disease and ALS, have had countless webinars whose social media campaign has touched tens of millions of people, with their subscriber list at tens of thousands.
CVBT/Venturis has now lost Myerson, CVBT has now lost yet another major court battle, Venturis has now lost the majority of their administration. What do we have? There are no experts running Venturis Therapeutics, those experts fled the company after they testified in court that CVBT was lying!
With Daniel C. Montano's $1 million dollar judgement against CVBT/Venturis Therapeutics (WHICH CVBT/VENTURIS HAS NO OFFSET) it is clear that Dan Montano will be coming after Cardiovascular Biotherapeutics.
Every Cardiovascular Biotherapeutics/Venturis Therapeutics shareholder has to keep up with Zhittya Genesis Medicine because they are our only competition! Our competition is leaving us in the dust, without a doubt they are six years ahead of us!
Ultimately I must ask, Zhittya Genesis Medicine has proven that in 6 years a lot of progress can be made. Where is CVBT/Venturis Therapeutics progress? We have made no drug, we have had no shareholders meeting, we have done nothing but lose court battle after court battle in the last half decade. We are losing. When will our CVBT management respond?
Every CVBT shareholder should care.
